Diabetes is a complex metabolic disease characterized by high blood glucose level.[@ref1] Its macrovascular complications include atherosclerosis, and its microvascular complications include damage to the kidney, nerves and eyes.[@ref2] Oxidative stress is increased in diabetes,[@ref3] therefore, it is considered as a cause of development of atherosclerosis.[@ref4] In diabetic patients, atherosclerosis is one of the most important causes of mortality.[@ref5] Human paraoxonase (PON-1) which is an antioxidant (via scavenging of free radicals),[@ref6] is synthesized in the liver and secreted into blood, where it is associated with high density lipoprotein (HDL) levels,[@ref7] and serum paraoxonase levels are inversely related to the risk of cardiovascular disease.[@ref8][@ref9] Some studies found that PON-1 activity is decreased in cardiovascular and diabetes mellitus.[@ref10][@ref11]

Vitamin C is an important antioxidant in human,[@ref12][@ref13] however, several studies showed vitamin C level in diabetic patients is decreased.[@ref14][@ref15] Vitamin A is a hydrophobic antioxidant[@ref16][@ref17] which is decreased in diabetes causes retinopathy.[@ref18] Also, vitamin E is a hydrophobic antioxidant which is found in membranes as well as lipoproteins and can afford primary as well as secondary stage protection against ROS activity.[@ref12][@ref19] Many studies showed the association between intake of omega-3 fatty acids and decreased risk of coronary heart disease[@ref20][@ref21] and its mortality.[@ref21] Studies with evaluation of the metabolic effect of omega-3 fatty acids on serum vitamins A, E, C in patients with type 2 diabetes are rare in literature. In addition, the metabolic effect of omega-3 fatty acids in patients with type 2 diabetes is not fully clear. There is also no evidence about the effect of omega-3 fatty acids in patients with type 2 diabetes in Iranian population. The aim of this study was to determine the effect of omega-3 fatty acids on paraoxonase activity, as well as the levels of vitamin A, C and E in Iranian diabetic type 2 patients.

Methods {#sec1-1}
=======
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### Study design {#sec3-1}

The present study was a randomized double blind placebo-controlled study financially supported by Tehran University of Medical Science (research project number: 2296). Study subjects included 80 type 2 diabetic patients (aged 45-80 years) with at least 2 years of diagnosed diabetes since onset of the condition. The subjects had a written consent to enroll into the study from Iranian Diabetes Association, Tehran, Iran using written announcement. They were divided randomly into two groups (experiment and control, n = 41 and n = 40, respectively) using computer\'s random numbers. Subjects had their routine medication regimens. Patients did not take omega-3 fatty acid supplements and/or medications interacting with lipid profile, did not have hepatic or renal disease, and had no history of cancer or myocardial infarction. Each patient received 3 capsules per day for 8 weeks. The dose of the supplements was chosen from other studies[@ref22]. The supplement was obtained from PBL Company, US. Omega-3 fatty acid dose was 2714 mg (EPA= 1548 mg, DHA= 828 mg and 338 mg of other omega-3 fatty acids) via 3 gel capsules. Placebo consisted of 3 capsules containing 2100 mg sunflower oil (12% SFA, 65% linoleic acid, and 23% MUFA). Placebo capsules looked identical and were prepared for this study by Zakaria Inc., Tehran, Iran.

### Data collection {#sec3-2}

Anthropometric data, medical and drug history were obtained via face-to-face interviews. Ten milliliter blood was collected from each patient after 12-14 hours overnight fasting, before taking oral hypoglycemia drugs, between 8-10 a.m., at the beginning and at the end of 8 weeks. Fasting blood sugar was measured. Paraoxonase (PON-1) activity and vitamin C were measured by spectrophotometry; and vitamin E and A were measured using HPLC. Daily nutrient intakes were estimated using 24-hour dietary recall questionnaires at the beginning and at the end of the study for 2 days. Dietary data were analyzed using Food Processor version 2 software. The patients were asked not to change their usual diets, activity and medications throughout the study.

### Statistical analysis {#sec3-3}

Differences between the two groups of supplemented and control groups were calculated using independent t-test. Differences between variables before and after interventions were calculated using paired t-test. Statistical analyses were performed using SPSS 11 (compatible with Microsoft Windows). The results are expressed as mean ± SD (standard deviation). For statistical evaluations, P value of less than 0.05 was considered as a significant change.

Results {#sec1-2}
=======

The clinical and demographic characteristics of subjects are shown in [Table 1](#T1){ref-type="table"}. Participants in case or control groups had equal age, sex, BMI, glucose and duration of diabetes at the beginning of the study (P \> 0.05). As shown in [Table 2](#T2){ref-type="table"}, energy and nutrient intake before and after intervention were also equal. [Table 3](#T3){ref-type="table"} shows that there was no significant difference in serum paraoxonase activity between the two groups before and after intervention, but after 8 weeks of omega-3 supplementation, serum paraoxonase activity was increased compared to its activity before treatment (P=0.002). [Table 4](#T4){ref-type="table"} presents the serum concentration of vitamins (A, E and C) in subjects before and after supplementation. At the beginning of the study, 2 groups were similar by the means of vitamins level. Following 2 months of supplementation, serum levels of vitamins A, E, C were not significantly changed in the case group.
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Comparison of dietary intake of macro- and micro-nutrients between two groups of study
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Paraoxonase (arylesterase) (IU/mL) activity before and after 2 months omega-3 supplementation in type 2 diabetic patients
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###### 

Levels of vitamin A, E (μmol/L) and vitamin C (mg/dl) before and after 2 months omega-3 supplementation in type 2 diabetic patients
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[Table 4](#T4){ref-type="table"} presents the serum concentration of vitamins (A, E and C) in subjects before and after supplementation. At the beginning of the study, two groups were similar by the means of vitamin levels. Following 2 months of supplementation, serum levels of vitamins A, E, C were not significantly changed in the case group.

Discussion {#sec1-3}
==========

It is believed that oxidative stress plays an important role in the pathogenesis of type II diabetes.[@ref23] Many studies on diabetes mellitus have showed that free radicals can cause chronic complications such as cardiovascular disease.[@ref24] Paraoxonase protects low density lipoprotein (LDL) and high density lipoprotein (HDL) against oxidative modification.[@ref25] It is believed that the oxidation of LDL is the first stage of development of atherosclerosis.[@ref26] Mackness and Karabina found that paraoxonase activity decreases in cardiovascular disease as well as in diabetes mellitus.[@ref10][@ref11] Omega-3 fatty acids are a class of polyunsaturated fatty acids that found in fish and fish oils.[@ref27] Omega-3 fatty acids from seafood and plant sources can reduce coronary heart disease.[@ref28] Our previous studies showed that omega-3 PUFA can decrease the inflammation in a cell culture model.[@ref29] The possible mechanism of anti-inflammatory effect of omega-3 PUFA is the decreased levels of arachidonic acid inflammatory pathway in the cells.[@ref30] However, it is believed that these fatty acids has no antioxidant activity and increase the utilization of the antioxidants.[@ref30] In our study, it is found that paraoxonase activity increased following omega-3 supplements. The changes in paraoxonase activity were observed after 8 weeks of supplementation of omega-3 by Calabresi.[@ref31] In other studies, it has been found that plasma concentration of HDL-bound antioxidant paraoxonase enzyme increased by 10% after omega-3 supplementation[@ref31] which is in the same track of our study.

Increased oxidative stress in diabetes could contribute to depletion of antioxidants.[@ref32] Several studies showed decreased basal vitamin C levels (a potent water phase antioxidant) in diabetic patients.[@ref33][@ref34] There are conflicting reports regarding plasma vitamin concentrations in diabetes mellitus. Merzouk found no alteration in the levels of serum vitamin C, whereas the levels of vitamin A and E were lower in type I and type II diabetes mellitus patients with or without complications than in control subjects.[@ref35] Studies also reported that plasma vitamin C and E in type II diabetic patients were not significantly different from those in control groups, while vitamin A levels were significantly lower.[@ref36][@ref37] On the other hand, Sundaram reported low levels of vitamin E and C in diabetic patients.[@ref38] Basu showed that the concentration of serum vitamin A and its binding protein, RBP, were lower in patients with diabetes than in normal control subjects.[@ref39] The present study demonstrated no significant change in vitamin A, C and E after consumption of omega-3 fatty acids. Zhou demonstrated that α-linolenic acid deficiency decreased DHA and elevated Osbond acid (OA) levels in tissue membranes, and dietary vitamin A deficiency had an important effect on membrane DHA and OA in rat tissues.[@ref40][@ref41] However, the effect of omega-3 on vitamin A, C and E in diabetic patients has not been studied recently.

Conclusion {#sec1-4}
==========

The present study demonstrated for the first time, that there was no significant change in vitamin A, C and E after consumption of omega-3 fatty acids. We concluded that omega-3 fatty acid supplementation (3 g/per day) in the form of capsules can increase paraoxonase activity in diabetic patients. The metabolic effect of omega-3 fatty acid in diabetic patients is less studied.
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